ArticlePloS one2015
Functional Metagenomics of the Bronchial Microbiome in COPD.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The alterations of oral, airway and intestine microbiota in chronic obstructive pulmonary disease: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- The respiratory microbiota alpha-diversity in chronic lung diseases: first systematic review and meta-analysis.Respiratory research · 2022Pooled it
- Reversing metabolic dysregulation in farnesoid X receptor knockout mice via gut microbiota modulation.PloS one · 2025Article
- Burn inhalation injury and intubation with dexamethasone-eluting endotracheal tubes modulate local microbiome and alter airway inflammation.Frontiers in bioengineering and biotechnology · 2025Article
- Detailed Characterization of the Lung-Gut Microbiome Axis Reveals the Link between PD-L1 and the Microbiome in Non-Small-Cell Lung Cancer Patients.International journal of molecular sciences · 2024Article
- The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression.Cells · 2023Review
- Alterations of lung microbiota in patients with non-small cell lung cancer.Bioengineered · 2022Article
- LDMD: A database of microbes in human lung disease.Frontiers in microbiology · 2022Article
- Lung microbiome of stable and exacerbated COPD patients in Tshwane, South Africa.Scientific reports · 2021Article
- The lung microbiome: progress and promise.The Journal of clinical investigation · 2021Review
- The Role of Respiratory Flora in the Pathogenesis of Chronic Respiratory Diseases.BioMed research international · 2021Review
- The airway microbiota and exacerbations of COPD.ERJ open research · 2020Article
- Review
- Methods in Lung Microbiome Research.American journal of respiratory cell and molecular biology · 2020Review
- Profiling of lung microbiota discloses differences in adenocarcinoma and squamous cell carcinoma.Scientific reports · 2019Article
- Smoking and microbiome in oral, airway, gut and some systemic diseases.Journal of translational medicine · 2019Review
- Microfluidics-Based Enrichment and Whole-Genome Amplification Enable Strain-Level Resolution for Airway Metagenomics.mSystems · 2019Article
- Airway microbiome research: a modern perspective on surveillance cultures?Annals of translational medicine · 2017Review
- Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease.Chinese medical journal · 2017Review
- Microbiome in chronic obstructive pulmonary disease.Annals of translational medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The course of chronic obstructive pulmonary disease (COPD) is frequently aggravated by exacerbations, and changes in the composition and activity of the microbiome may be implicated in their appearance. The aim of this study was to analyse the composition and the gene content of the microbial community in bronchial secretions of COPD patients in both stability and exacerbation. Taxonomic data were obtained by 16S rRNA gene amplification and pyrosequencing, and metabolic information through shotgun metagenomics, using the Metagenomics RAST server (MG-RAST), and the PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) programme, which predict metagenomes from 16S data. Eight severe COPD patients provided good quality sputum samples, and no significant differences in the relative abundance of any phyla and genera were found between stability and exacerbation. Bacterial biodiversity (Chao1 and Shannon indexes) did not show statistical differences and beta-diversity analysis (Bray-Curtis dissimilarity index) showed a similar microbial composition in the two clinical situations. Four functional categories showed statistically significant differences with MG-RAST at KEGG level 2: in exacerbation, Cell growth and Death and Transport and Catabolism decreased in abundance [1.6 (0.2-2.3) vs 3.6 (3.3-6.9), p = 0.012; and 1.8 (0-3.3) vs 3.6 (1.8-5.1), p = 0.025 respectively], while Cancer and Carbohydrate Metabolism increased [0.8 (0-1.5) vs 0 (0-0.5), p = 0.043; and 7 (6.4-9) vs 5.9 (6.3-6.1), p = 0.012 respectively]. In conclusion, the bronchial microbiome as a whole is not significantly modified when exacerbation symptoms appear in severe COPD patients, but its functional metabolic capabilities show significant changes in several pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.